Clinical trial
An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
NCT03580655 is registered in ClinicalTrials.gov with Blueprint Medicines Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
- Lead sponsor
- Blueprint Medicines Corporation
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 21, 2018
- Completion date
- December 18, 2024
- Enrollment
- 107 (actual)
- Sites
- 32
Conditions
As the registry lists them; a condition with its own page is linked.
advanced systemic mastocytosis, aggressive systemic mastocytosis, mast cell leukemia, systemic mastocytosis with an associated hematologic neoplasm